AU636453B2 - An improved toxin for construction of immunotoxins - Google Patents

An improved toxin for construction of immunotoxins Download PDF

Info

Publication number: AU636453B2
Authority: AU; Australia
Prior art keywords: cells; lyspe40; molecule; domain; tumor
Prior art date: 1989-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU71723/91A

Other languages

English (en)

Other versions

AU7172391A (en

Inventor

David Fitzgerald

Ira H. Pastan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

United States Department of Commerce

Original Assignee

US Department of Health and Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-21

Filing date

1990-12-21

Publication date

1993-04-29

1990-12-21 Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services

1991-07-24 Publication of AU7172391A publication Critical patent/AU7172391A/en

1993-04-29 Application granted granted Critical

1993-04-29 Publication of AU636453B2 publication Critical patent/AU636453B2/en

2010-12-21 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000003053 toxin Substances 0.000 title claims description 5
231100000765 toxin Toxicity 0.000 title claims description 5
239000002596 immunotoxin Substances 0.000 title description 28
231100000608 immunotoxin Toxicity 0.000 title description 28
229940051026 immunotoxin Drugs 0.000 title description 28
230000002637 immunotoxin Effects 0.000 title description 27
238000010276 construction Methods 0.000 title description 7
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 23
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 13
230000001472 cytotoxic effect Effects 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
231100000433 cytotoxic Toxicity 0.000 claims description 9
238000012217 deletion Methods 0.000 claims description 8
230000037430 deletion Effects 0.000 claims description 8
230000003013 cytotoxicity Effects 0.000 claims description 7
231100000135 cytotoxicity Toxicity 0.000 claims description 7
102000005962 receptors Human genes 0.000 claims description 7
108020003175 receptors Proteins 0.000 claims description 7
239000003446 ligand Substances 0.000 claims description 6
230000008878 coupling Effects 0.000 claims description 3
238000010168 coupling process Methods 0.000 claims description 3
238000005859 coupling reaction Methods 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
230000006872 improvement Effects 0.000 claims description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
239000004472 Lysine Substances 0.000 claims 1
239000003102 growth factor Substances 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 description 54
210000004027 cell Anatomy 0.000 description 34
108090000623 proteins and genes Proteins 0.000 description 20
241000699670 Mus sp. Species 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 12
230000000694 effects Effects 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
241000699660 Mus musculus Species 0.000 description 9
238000011580 nude mouse model Methods 0.000 description 9
230000036765 blood level Effects 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000001243 protein synthesis Methods 0.000 description 7
239000000463 material Substances 0.000 description 6
230000014616 translation Effects 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
108010079246 OMPA outer membrane proteins Proteins 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000012634 fragment Substances 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
102000007238 Transferrin Receptors Human genes 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
238000003556 assay Methods 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
239000000499 gel Substances 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000001338 necrotic effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000012064 sodium phosphate buffer Substances 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
101100321445 Arabidopsis thaliana ZHD3 gene Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000012010 growth Effects 0.000 description 2
102000055277 human IL2 Human genes 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
101150074154 pe gene Proteins 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000672609 Escherichia coli BL21 Species 0.000 description 1
YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
239000012614 Q-Sepharose Substances 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
102100031013 Transgelin Human genes 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000001516 effect on protein Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000011255 standard chemotherapy Methods 0.000 description 1
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU71723/91A 1989-12-21 1990-12-21 An improved toxin for construction of immunotoxins Ceased AU636453B2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45416289A	1989-12-21	1989-12-21
US454162		1989-12-21

Publications (2)

Publication Number	Publication Date
AU7172391A AU7172391A (en)	1991-07-24
AU636453B2 true AU636453B2 (en)	1993-04-29

Family

ID=23803558

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU71723/91A Ceased AU636453B2 (en)	1989-12-21	1990-12-21	An improved toxin for construction of immunotoxins

Country Status (5)

Country	Link
EP (1)	EP0506854A4 (fr)
JP (1)	JPH04506976A (fr)
AU (1)	AU636453B2 (fr)
CA (1)	CA2071946A1 (fr)
WO (1)	WO1991009965A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6329508B1 (en)	1989-09-07	2001-12-11	Alkermes, Inc.	Transferrin receptor reactive chimeric antibodies
US5527527A (en) *	1989-09-07	1996-06-18	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) *	1989-09-07	1997-09-30	Alkermes, Inc.	Transferrin neuropharmaceutical agent fusion protein
WO1993010819A1 (fr) *	1991-11-26	1993-06-10	Alkermes, Inc.	Procede de preparation de conjugues d'agents diagnostiques ou neuropharmaceutiques-anticorps specifiques de recepteur de transferine
US5977307A (en) *	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5571894A (en) *	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US5939531A (en) *	1991-07-15	1999-08-17	Novartis Corp.	Recombinant antibodies specific for a growth factor receptor
US6066718A (en) *	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
US6015555A (en) *	1995-05-19	2000-01-18	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US8932586B2 (en)	2011-09-06	2015-01-13	Intrexon Corporation	Modified forms of Pseudomonas exotoxin A
WO2016146833A1 (fr)	2015-03-19	2016-09-22	F. Hoffmann-La Roche Ag	Biomarqueurs de résistance à la nad(+)-diphtamide adp-ribosyltransférase
EP3184547A1 (fr)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anticorps anti-tpbg et procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4545985A (en) *	1984-01-26	1985-10-08	The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services	Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) *	1986-09-24	1990-01-09	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects

1990
- 1990-12-21 WO PCT/US1990/007464 patent/WO1991009965A1/fr not_active Ceased
- 1990-12-21 CA CA002071946A patent/CA2071946A1/fr not_active Abandoned
- 1990-12-21 AU AU71723/91A patent/AU636453B2/en not_active Ceased
- 1990-12-21 EP EP19910902540 patent/EP0506854A4/en not_active Withdrawn
- 1990-12-21 JP JP91502841A patent/JPH04506976A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4545985A (en) *	1984-01-26	1985-10-08	The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services	Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) *	1986-09-24	1990-01-09	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects

Also Published As

Publication number	Publication date
EP0506854A1 (fr)	1992-10-07
JPH04506976A (ja)	1992-12-03
EP0506854A4 (en)	1992-11-19
WO1991009965A1 (fr)	1991-07-11
AU7172391A (en)	1991-07-24
CA2071946A1 (fr)	1991-06-22

Publication	Publication Date	Title
Kondo et al.	1988	Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.
US5863745A (en)	1999-01-26	Recombinant antibody-toxin fusion protein
US5696237A (en)	1997-12-09	Recombinant antibody-toxin fusion protein
US6099842A (en)	2000-08-08	Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
Batra et al.	1989	Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
JP3553933B2 (ja)	2004-08-11	高められた活性を有する組換シュードモナス外毒素
Batra et al.	1991	Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR (Fv)-PE40 and DT388-anti-TFR (Fv)
EP0469065B1 (fr)	1996-05-29	Proteine recombinante de fusion anticorps-toxine
AU636453B2 (en)	1993-04-29	An improved toxin for construction of immunotoxins
US5690928A (en)	1997-11-25	Method of treating bladder cancer cells
WO1994004689A1 (fr)	1994-03-03	Toxine recombinee a demi-vie prolongee
Debinski et al.	1994	An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin
Choe et al.	1994	B3 (Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3
Ogata et al.	1991	Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes
Siegall et al.	1990	Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels.
Debinski et al.	1995	Recombinant F (ab') C242-Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft.
NZ238583A (en)	1994-02-25	Targetted cytotoxic anticancer conjugates and
IE84490B1 (en)	2007-02-07	Recombinant pseudomonas exotoxin: construction of an active immunotoxin with low side effects